Enamine's Coronavirus Library is designed for the discovery of new SARS-CoV-2 and pan-Coronavirus antivirals, containing 16,800 compounds.
Enamine’s Coronavirus Library is designed for the discovery of new SARS-CoV-2 and pan-Coronavirus antivirals, containing 16,800 compounds.
To meet the urgent need for potent new antivirals against Covid-19, Enamine has designed and pre-plated for quick delivery a small-molecule compound library focusing on most promising targets to fight coronaviruses.
We have focused design efforts on the following targets reported to be important for viral life cycle, transmission and replication. All reported earlier actives were analysed and close analogues were included to the library.
- SARS-CoV-2 main protease Mpro(also called 3CLpro)
- RNA-dependent RNA polymerase (RdRp)
- Papain-like protease (PLpro)
- Angiotensin-converting enzyme 2 (ACE2) receptor
- Type-II and 11e transmembrane serine protease (TMPRSS2 and TMPRSS11e)
- Non-structural proteins (NSP) of SARS/MERS-CoV/-2, with reported 3D-structure.
The Coronavirus Library consists of five sublibraries, which can be also acquired separately.
This library incarnates Enamine’s rich experience in the design and synthesis of antiviral compounds. We take an active part in the global open science initiative Covid Moonshot project, providing synthesis, ADME-Tox profiling, medicinal chemistry, and logistics services.